ISSN: 0975-8585
Research Journal of Pharmaceutical, Biological and Chemical
Sciences
Screening of CTX-M T pe E te ded Spectru ΒETA-Lactamases Producing
Clinical Isolates from Tamil Nadu, India.
Ramesh N*, Prasanth M, Avani Patel, Mihir Shah, Parth Agrawal, and Gothandam KM.
School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
ABSTRACT
The world is facing a major problem of antimicrobial resistance that is more severe in developing
countries where the infectious diseases get spread more easily and the cost of treatment and prevention of
them is very high. Multidrug resista e a d e te ded spe tru β-lactamases (ESBL) production is a common
problem, which needs empirical therapy to overcome and to reduce this drug resistance. In this study 88
clinical isolates were studied for ESBL production and presence of CTX-M genotypically. Out of 88 isolates, 32
were Escherichia coli (36%), 20 Klebsiella pneumoniae (23%), 14 Pseudomonas aeruginosa (16%), 12
Enterobacter cloacae (14%), 3 Proteus vulgaricus (3%), 5 Proteus mirabilis (7%) and 2 Acinetobacter baumannii
(2%). Antibiotic susceptibility pattern showed 92% of the isolates were resistant to most beta-lactam
antibiotics and plasmid was isolated from 72 isolates irrespective of its susceptibility pattern. 29 isolates were
found to have CTX-M group I genes that includes 17 of 32 E. coli (53%), 8 of 20 K. pneumoniae (40%), 1 of 14 P.
aeruginosa (7%) and 3 of 12 Enterobacter cloacae (25%). This study describes the genetic characteristics and
molecular epidemiology of ESBLs among Enterobacteriaceae isolates and provides insight emergence of
bacterial strains harbouring ESBL genes.
Keywords: Gram negative bacteria, beta-lactamase, multi-drug resistant, plasmid profile, phenotypic variants.
*Corresponding author
July– August
2015
RJPBCS
6(4)
Page No. 658
ISSN: 0975-8585
INTRODUCTION
Extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, especially Klebsiella
pneumoniae and Escherichia coli, were shown to have a significant impact on treatment options and clinical
outcome in patients [1]. Further, ESBL- producing bacteria have shown to cause higher morbidity, mortality
and fiscal burden [2]. Enterobacteriaceae produci g β-lactamase displaying multi-drug resistance and causing
therapeutic problems have been found in human and veterinary practice [3]. ESBLs are dangerous, as they are
plasmid associated and there can be a cross species- dissemination of these plasmids. Moreover, these
plasmids can carry co-resistance of antibiotics such as aminoglycosides, fluroquinolones, tetracycline,
chloramphenicol and sulfamethoxazole-trimethoprim [4]. As ESBLs are the main reason of multi-drug
resistance (MDR) in Gram negative clinical pathogens, their early detection and identification of the resistance
enzymes will help us to optimize antimicrobial therapy and to prevent the spread of these organisms in
hospitals and outbreak of any epidemic symptoms [5]. The most important mechanism of resistance in
li i all sig ifi a t a teria is the produ tio of o e or ore β-la ta ase e z es, hi h h drol ze the βla ta ri g of β- lactam antibiotics. ESBL, a plasmid-mediated trait typically found in Enterobacteriaceae, is an
emerging public health problem. An excessive use of antibiotics to prevent and reduce the frequency of
infections has led to the selection and emergence of resistant bacteria, and they are involved in variety of
infections like urinary tract infection (UTI) [6], septicaemia, hospital acquired pneumonia, intra-abdominal
abscess, brain abscess, surgery device related infections and also from environments such as touch screens of
ATM machines [7].
METHODOLOGY
Identification of clinical isolates
A total of 88 clinical isolates were isolated from 300 samples, recovered from patients infected with
Enterobacteriaceae within the ages of 3 to 58 among both genders during August 2013 to November 2014 of
tertiary care hospitals in North Eastern part of Tamil Nadu. Clinically significant bacteria were isolated by using
standard microbiological procedures and identified at species level by automated methods with mini Api
identification system. The study was carried out in Antibiotic resistance laboratory, VIT University, Vellore.
Antibiotic Susceptibility Pattern
Antibiotic susceptibility testing of the isolates was performed by the disk diffusion method, as per
Clinical Laboratory Standard Institute [8] guidelines. Briefly, the inoculum was adjusted to the turbidity of
0.5McFarland was swabbed on to MH agar plates and commercial antibiotic disks were used (Hi-Media,
Mumbai, India). The concentrations of used antibiotics were ampicillin (10µcg), amikacin (30µcg), gentamycin
(10µcg), ciprofloxacin (5µcg), norfloxacin (10µcg), levofloxacin (5µcg), nitrofurontoin (30µcg), tobramycin
(10µcg), ceftriaxone (30µcg), cefotaxime (30µcg), cefoxitin (30µcg), ceftazidime (30µcg), cefuroxime (30µcg),
cefepime (30µcg), co-trimoxazole (25µcg), amoxicillin clavulanic acid (30µcg), imipenem (10µcg), meropenem
(10µcg), piperacillin tazobactum (100/10µcg), ticarcillin clavulanic acid (75/10µcg), and Nitrofurantoin. The
antibiotic potency of the disks was standardised against the reference strains.
Molecular studies
Plasmid profiling was done by using the plasmid DNA obtained by modified alkaline lysis method. PCR
amplification for blaCTX-M group genes was carried out for all the isolates using PCR conditions and primers
(Table-1) as previously described [9]. The selected PCR product sequence analysis was done using the Big Dye
terminator cycle sequencing method (Applied Biosystems3730 and 3730xl) in (Macrogen) and compared to
sequences within the NCBI database (http://www/ncbi.nlm.nih.gov/) by using Basic Local Alignment Search
Tool (BLAST) [10].
July– August
2015
RJPBCS
6(4)
Page No. 659
ISSN: 0975-8585
Table 1: PCR primer sequences for CTX-M group genes.
Primer Name
CTX-M group 1 – f
CTX-M group 1 – r
CTX-M group 2 – f
CTX-M group 2 – r
CTX-M group 9 – f
CTX-M group 9 – r
CTX-M group 26 – f
CTX-M group 8/26 – r
CTXM group 8 fwdII
Primer Sequence (5'-3')
AAAAATCACTGCGCCAGTTC
AGCTTATTCATCGCCACGTT
CGACGCTACCCCTGCTATT
CCAGCGTCAGATTTTTCAGG
CAAAGAGAGTGCAACGGATG
ATTGGAAAGCGTTCATCACC
GCACGATGACATTCGGG
AACCCACGATGTGGGTAGC
TCGCGTTAAGCGGATGATGC
Product Size (bp)
415
415
552
552
205
205
327
327 or 666
666
RESULTS
Identification of isolates
Number of isolates
Out of 88 isolates, the most encountered pathogenic organisms were Escherichia coli (36%) followed
by Klebsiella pneumoniae (23%), Pseudomonas aeruginosa (16%), Enterobacter cloacae (14%), Proteus
vulgaricus (3%), Proteus mirabilis (7%) and Acinetobacter baumannii (2%) (Fig.1.).
35
30
25
20
15
10
5
0
Number of isolates
Number of CTX-M positive
Figure 1: Comparison of CTX-M group gene positive isolates with total number of isolates.
Antibiotic susceptibility pattern
Among 88 bacterial pathogens isolated from the clinical specimens, 81 (92%) strains were
phenotypically resistant to ESBLs (Fig.2.). The antimicrobial sensitivity patterns showed the overall resistance
pattern of ceftriaxone was 88.8% followed by norfloxacin (95%), ciprofloxacin (88.8%), nitrofurantoin (45%),
co-trimoxazole (77.5%), cefoxitin (55.5%) and levofloxacin (77.5%) though Pseudomonas showed resistance
against norfloxacin (40%), levofloxacin (45%), tobramycin (60%), amikacin (60%), cefepime (40%) and
ceftazidime (40%) but 80% of klebsiella spp. showed resistance against cefuroxime axetil, ceftriaxone, cotrimoxazole, ciprofloxacin and levofloxacin. The strains of Proteus mirabilis and Proteus vulgaricus showed
maximum susceptibility against norfloxacin, levofloxacin, cefuroxime axetil, nitrofurantoin and ceftriazone. All
the isolates were found to have resistance against cephalosporins.
July– August
2015
RJPBCS
6(4)
Page No. 660
ISSN: 0975-8585
Figure 2: Antibiotic susceptibility test results with nine different beta-lactam antibiotic discs placed over MH agar
swabbed with E. coli (left) and K. pneumoniae (right).
Molecular studies
Out of 88 selected strains, 72 (82%) strains yielded plasmids, while the remaining 16 (18%) were
plasmid free. On agarose gel, multiple plasmids were observed for E. coli, Klebsiella spp. and Proteus spp.
Plasmid copy number in these isolates ranged from 5 to 7, while the remaining had a plasmid copy number of
1 to 4. Plasmid DNA was isolated from the ESBL producers and they were subjected to multiplex PCR for the
identification of blaCTX-M genes (Fig.3.). Of these 88 isolates, 29 strains (33%) were found positive for group I
CTX-M genes (CTX-M-15), that includes 17 of 32 E. coli (53%), 8 of 20 K. pneumoniae (40%), 1 of 14 P.
aeruginosa (7%) and 3 of 12 Enterobacter cloacae (25%) which is around 415bp in size. The sequenced gene
was submitted to NCBI (accession no - KJ131190.1) and the ESBL was identified as CTX-M-15 type.
Figure 3: Multiplex PCR amplification of CTX-M group genes. Lane 1-11 with clinical isolates positive for CTX-M group 1
gene and M- DNA molecular ladder.
DISCUSSION
The prevalence of CTX-M producing organisms has progressively increased and become a major
clinical problem worldwide. Infections by the ESBL producers are infamous for unfavourable outcomes and
high mortality rates. Our study showed Escherichia coli was the most prevalent strain with 36%, followed by
Klebsiella pneumoniae (23%) and Pseudomonas aeruginosa (16%). The isolates of E.coli showed maximum
susceptibility against ceftriaxone (88.8%), norfloxacin (95%), ciprofloxacin (88.8%), nitrofurantoin (45%), cotrimoxazole (77.5%), cefoxitin (55.5%) and levofloxacin (77.5%). High amount of ESBL-producing bacteria from
inpatients and outpatients indicates the continent wide spread of these species and particularly in E. coli with
great variations in distribution and occurrence among different countries. Haque et al., (2012) had showed
that the most prevalent isolates of Escherichia coli 58.6% and Pseudomonas 8.6% were resistance against most
of the antibiotics including cefazolin, ceftriaxone, cefuroxime, ampicillin and co-trimoxazole [4]. The
July– August
2015
RJPBCS
6(4)
Page No. 661
ISSN: 0975-8585
Pseudomonas showed resistance against norfloxacin (40%), levofloxacin (45%), tobramycin (60%), amikacin
(60%), cefepime (40%) and ceftazidime (40%). The isolates of Klebsiella pneumoniae showed resistance against
cefuroxime axetil (80%), cefepime (40%), co-trimoxazole (45%), amikacin (35%) and levofloxacin (50%). This
compared with the study by An et al.,(2012) reported that the resistance rated to drugs with lower overall
resistance to amikacin, cefeoime, piperacillin/tazobactum, cefotetan and imipenem were 26.6%, 22.2%, 10.1%,
8.2% and 3.8% respectively [11]. A study by Oleson et al., (2013) showed that out of 115 ESBL isolates, 92%
isolates produced CTX-M enzymes, most commonly 52% of CTX-M-15 [12]. A study by Achour et al., (2009) in
Klebsiella pneumoniae reported the first evidence of presence of CTX-M-28 gene by sequencing its PCR
products [13]. Another study reported that out of 140 E. coli strains screened for blaCTX-M group genes 50
showed (35.7%) presence of CTX-M group-1 genes [14]. In our study, all the blaCTX-M positive isolates (35%)
were found to have CTX-M group 1 gene that was already reported in Iran [14], France [15], Switzerland [16]
and Austria [17]. The remaining 52 isolates were found to be negative for blaCTX-M genes but they were
phenotypically positive indicating the possibility for presence of ESBLs other than CTX-M and this result do not
negate the possibility for other modified blaCTX-M in these isolates. As Gram negative organisms show increased
resistance towards beta-lactam antibiotics future surveillance studies should use both phenotypic and
genotypic tests for effective analysis. The high rate of ESBL production is due to the excessive use of broadspectrum antibiotics in clinical sectors with lack of attention towards ESBL production in clinical pathogens
[14]. May be spread of one single clone and/or plasmid is a reason for ESBL production with one common CTXM gene at higher rate within these clinical isolates and owing to a number of limitations we could sequence
only one CTX-M gene and could not determine the plasmid profiling for these isolates.
CONCLUSION
In the present study, Escherichia coli and Klebsiella pneumoniae were the species with highest ESBL
production and they showed the highest prevalence of blaCTX-M group 1 (CTX-M-15) gene. It was also to be
noted that not all phenotypically ESBL resistant isolates were found to have CTX-M group genes detected in
this study. The results of this study describe the genetic characteristics and molecular epidemiology of ESBLs
among Enterobacteriaceae isolates and provides insight emergence of bacterial strains harbouring ESBL genes.
There is an urgent need to monitor the spread of these ESBL producers throughout the glo e. If e do ’t gi e
proper importance to monitor this MDR, in future we may lose all available antibiotics.
ACKNOWLEDGEMENT
This author’s ould like to tha k DST-SERB Ref. No.: SERB/LS-930/2012, Govt. of India, New Delhi, for
funding source to this study.
REFERENCES
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
Meier S, Weber R, Zbinden R, Ruef C and Hasse B. Infect 2011; 39: 333–340.
Dhillon RH and Clark J. Crit Care Res Pract 2012; 625170.
Li L, Jiang ZG, Xia LN, Shen JZ, Dai L, Wang Y, Huang SY and Wu CM. Vet Microbio 2010; 144: 505–510.
Haque SF, Saeedut-Z Ali, Mohammed TP, Asad U Khan. Asian Pac J Trop Med 2012; 5(2): 98-102.
Willems E, Cartuyvels R, Magerman K and Verhaegen J. Diagn Microbiol Infect Dis 2013; 76:16–19.
Ramesh N, Sumathi CS, et al. Adv Biol Res 2008; 2(5-6): 78-82.
Ramesh N, Akshita Prakash Pillai, Nandini Rajannambiar, Prasanth M, Shanthini T, Gothandam KM,
Karthikeyan S. Asian J Pharma Clin Res 2015; 8(2): 409-411.
CLSI Clinical and Laboratory Standards Institute. M02-A11performance standards for antimicrobial
disk susceptibility tests. Wayne, PA: Clinical and Laboratory Standards Institute; 2011: 14.
Woodford N, Elizabeth J, Fagan and Matthew JE. J Antimicro Chemo 2006; doi:10.1093/jac/dki412.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. J Mol Biol 1990;215(3):403-410.
An S, Jichao chen, Zhanwei wang et al., FEMS Microbiol lett 2012; 332: 137-145.
Olesen B, Hansen DS, Nilsson F, Jakob et al., J. Clin. Microbiol 2013; 51(6):1779.
Anchour NB, et al. Pathologie Biologie 2009; 57: 343-348.
Mirzaee M, Parviz Owlia, Sadegh Mansouri. Labmed 2009; 40(12): 724-727.
Sanguinetti M, Posteraro B, Ciccaglione D, et al. J Clin Microbiol 2003;41:1463–1468.
Lartigue MF, Zinsius C, Wenger A, et al. Antimicrob Agents Chemother 2007;51: 2855–2860.
Lavigne JP, Marchandin H, Delmas J, et al. Antimicrob Agents Chemother 2006;50: 4224–4228.
July– August
2015
RJPBCS
6(4)
Page No. 662